Hemophilia Treatment Market, By Product Type (Plasma Derived Coagulation Factor, Recombinant Coagulation Factor, Antifibrinolytic Agents, and Desmopressin), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Mar 2023

Code : CMI2012

Pages :180

Formats :

Excel and PDF

Industry : Pharmaceutical

Leading Companies

Global Hemophilia Treatment Market - Key Developments

In January 2023, World Federation of Hemophilia (WFH), U.S. Food and Drug Administration (FDA), proposed individual risk assessment for blood donations in revision of U.S.A. donor eligibility and deferral policies. WFH Gene Therapy Registry (GTR) aims to collect important data on all patients who have received gene therapy either through clinical trials or post-marketed product.

In April 2020, the U.S. Food and Drug Administration approved HEMA Biologics’s, biopharmaceutical company’s sevenfact coagulation factor VIIa (recombinant)-jncw) for the adults and adolescents of 12 years of age and older with hemophilia A or B.

Global Hemophilia Treatment Market: Key Players

Major players operating in the global hemophilia treatment market include Takeda Pharmaceutical Co., Ltd.,Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, and F. Hoffmann-La Roche AG.